ResMed Inc. vs Solaris Energy Infrastructure Inc. Class A Common Stock — how do they compare? ResMed Inc. trades at $235.17 (market cap $32.99B), while Solaris Energy Infrastructure Inc. Class A Common Stock trades at $68.5 (market cap $5.12B). The key difference: ResMed Inc. is far larger — about 6.4× Solaris Energy Infrastructure Inc. Class A Common Stock's market cap, and ResMed Inc. pays the higher dividend (1.13%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days on average.
| RMD | SEI | |
|---|---|---|
Market Cap | $32.99B | $5.12B |
Volume | 1,023,381 | 2,532,496 |
Sector | Health | Energy |
52-Week High | $275.96 | $82.88 |
52-Week Low | $182.82 | $40.64 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $32.35B | $6.81B |
Dividend Yield | 1.13% | 0.62% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $235.29, up 0.29% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 27.2% net margins and consistent earnings beats in recent quarters. Recent news highlights include upcoming Q1 2027 earnings and management presentations at healthcare conferences, while analyst consensus remains positive with a $243.56 price target.
RMD presents a favorable investment case with strong profitability metrics and positive earnings momentum, though elevated valuation ratios and ongoing legal investigations warrant caution. The stock's technical strength supports near-term upside potential toward resistance levels, while fundamental growth drivers in sleep therapy demand provide long-term support.
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →